

**Dermatology Update 2008 Program as of April 4, 2008**

	Thursday April 10		Friday April 11		Saturday April 12	
7am-9am	<b>Ad. Board</b> 7:00am – 9:00am Controversies in Conventional Acne Therapy <i>(by invitation)</i>		<b>Ad. Board</b> 7:00am – 9:00am Raptiva Restore Investigator Meeting <i>(by invitation)</i>	<b>Ad. Board</b> 7:00am – 9:00am The Practical Treatment of Atopic Dermatitis: A Global Perspective <i>(by invitation)</i>	<b>Ad. Board</b> 7:00am – 9:00am Professional Selling Workshop <i>(by invitation)</i>	<b>Ad. Board</b> 7:00am – 9:00am Linking the Product Profile and Clinical Benefits of Novel Psoriasis Treatment Options to the Efficient Management of your Psoriasis Patients in Practice <i>(by invitation)</i>
7:30am-9am	Chateau Buffet Breakfast		Chateau Buffet Breakfast		Chateau Buffet Breakfast	
9am-10am	<b>Plenary Session</b> 9:05am – 10:30am		<b>Plenary Session</b> 9:05am – 10:20am		<b>Plenary Session</b> 9:05am – 10:35am	
10am-11am	9:05 – 9:15 Opening Comments 9:15 – 9:45 Skin Therapy Update - <i>Stuart Maddin</i> 9:45 – 10:15 The New Immune System Targets in the Treatment of Psoriasis – The IL-12 and IL-23 Cytokine Family - <i>James Krueger</i> 10:15 – 10:30 Raptiva® in psoriasis: A trusted therapy for enduring disease clearance - <i>Chih-Ho Hong</i> 10:30 – 10:45 Q&A		9:05 – 9:20 The Future Management of Psoriasis - <i>Giampiero Girolomoni</i> 9:20 – 9:35 DermaDNA™: The Use of Mitochondrial DNA as a “Biosensor” for UVR Induced Skin Damage in relation to the genetic determination of skin type: Implications for Personalized Skin Care. - <i>Mark Birch-Machin</i> 9:35 – 9:50 Etanercept Treatment in Children and Adolescents with Plaque Psoriasis - <i>Richard Langley</i> 9:50 – 10:05 Biologics: What Can You Really Expect After the Initial Treatment? - <i>Yves Poulin</i> 10:05 – 10:20 Q&A		9:05 – 9:20 Skin Cancer Update in the Transplant Population - <i>Claas Ulrich</i> 9:20 – 9:35 TBA - <i>Mark Lebwohl</i> 9:35 – 9:50 Whither Goes IRM? - <i>Ted Rosen</i> 9:50 – 10:05 University to Private Practice: The Ethics of Professional Selling – <i>Cherie Ditre</i> 10:05 – 10:15 Canadian Skin Patient Alliance – <i>Christine Jackson</i> 10:15 – 10:30 Q&A	
11am-12pm	<b>Clinical Trials Workshop</b> 10:45am – 12:15pm <i>(by pre-registration)</i>		<b>Open Session</b> 10:30am – 12:00pm Cosmeceuticals - Practical Solutions for Common Problems		<b>Open Session</b> 10:50am – 12:05pm Getting to the Root of the Problem: <i>Delving into psoriasis, common comorbidities, and therapeutic options</i>	
12pm-1pm	<b>SKI BREAK</b> 10:45am – 3:00pm		<b>SKI BREAK</b> 12:05pm – 3:00pm		<b>Ad. Board</b> 12:15pm – 2:15pm Patient and Clinic Support: Defining Dermatology Needs <i>(by invitation)</i>	<b>Ad. Board</b> 12:15pm – 2:15pm Managing Moving Towards Optimal Topical Therapy for Psoriasis <i>(by invitation)</i>
1pm-2pm						
2pm-3pm						
3pm-4pm	<b>Ad. Board</b> 3:00pm – 5:00pm Workshop on Acne and Anti-Fungal <i>(by invitation)</i>	<b>Ad. Board</b> 3:00pm – 5:00pm Update in Pediculosis Management & Assessing Nycomed Dermatology Pipeline <i>(by invitation)</i>	<b>Ad. Board</b> 3:00pm – 5:00pm Challenging Cases in the Therapeutics of Psoriasis: A Female Dermatologist's Perspective <i>(by invitation)</i>		<b>Plenary Session</b> 2:30pm – 4:00pm 2:30 – 2:40 Ice & Hyperhidrosis – <i>Kevin Smith</i> 2:40 – 2:45 BTX & facial fillers - <i>Kevin Smith</i> 2:45 – 3:00 Management of Hair Loss in Women - <i>Jerry Shapiro</i> 3:00 – 3:15 The Burden of Psoriasis and Psoriatic Arthritis in Canada: Insights from the Psoriasis Knowledge in Canada (SKIN) Survey - <i>Chuck Lynde</i> 3:15 – 3:30 Realistic treatment option for persistent acne (2008)- <i>Jerry Tan</i> 3:30 – 3:45 Restoring natural-looking, long-lasting volume with Sculptra injectable poly-L-lactic acid - <i>Wayne Carey</i> 3:45 – 4:00 Q&A 4:00 – 4:10 Closing Comments	
4pm-5pm	<b>Open Session</b> 5:15pm – 6:30pm Novel Psoriasis Treatment Options: The Clinical Results of Targeting IL-12 and IL-23		<b>Open Session</b> 5:15pm – 6:30pm Practical Perspectives in a Biologic Era of Psoriatic Disease		<b>Open Session</b> 4:15pm – 5:30pm What's New in the Treatment of Non-Melanoma Skin Cancer?	
6pm-7pm	<b>BC Wine Tasting Reception</b> 6:30pm – 7:30pm				<b>Closing Reception</b> 5:30pm – 7:00pm	
7pm-8pm						
8pm -9pm	<b>Ad. Board</b> 7:00pm – 10:30pm ENBREL Advisory Board <i>(by invitation)</i>					

**Novel Psoriasis Treatment Options: The Clinical Results of Targeting IL-12 and IL-23**

Thursday April 10<sup>th</sup>, 2008

5:15pm to 6:30pm

**Objectives:**

- To investigate the current unmet medical needs that exist for effective therapies with limited toxicity and side effects
- To uncover whether the blocking of IL-12 and IL-23 with antibodies may lead to improvement in psoriasis outcomes
- To discuss the new clinical trial data on monoclonal antibodies targeted toward the IL-12 and IL-23 blockade in psoriasis

**Cosmeceuticals – practical solutions for common problems**

Friday April 11<sup>th</sup>, 2008

10:30am to 12:00pm

Chaired by Dr Jeffrey Dover with special Cdn panelists

**Agenda:**

Introduction - *Dr Lee Bansil PhD, P&G*

"Cosmeceuticals- practical solutions for common problems' – *Dr Jeffrey Dover*  
Q&A

Canadian Panel discussion

Q&A and Wrap up

**Practical Perspectives in a Biologic Era of Psoriatic Disease**

Friday April 11<sup>th</sup>, 2008

5:15pm to 6:30pm

**Program Objectives:**

Discuss, in a practical, case based approach:

- 1) Optimal management of "problem psoriasis"
- 2) Patient management issues pertaining to appropriate patient selection, screening and safety considerations when choosing a biologic therapy.

**Dr. Marc Bourcier** - (Moncton, NB) - Chair (10 mins)  
Program introduction and objectives.

**Dr. Marc Lebwohl** - (New York, NY)

**Topic: Problem Psoriasis** (25mins)

Learning objectives:

- 1) Identify and learn how to effectively counsel your problem psoriasis patient
- 2) Discuss the role of systemic therapies in problem psoriasis
- 3) Discuss the role of biologic therapies in problem psoriasis
- 4) Discuss combination treatment strategies for these difficult (recalcitrant) patients

**Dr. Richard Langley** - (Halifax, NS)

**Topic: Practical Aspects of Biologic Therapy in Psoriatic Disease – Safety Considerations** (25 mins)

Learning objectives:

- 1) Identify potential safety aspects when considering biologic therapy
- 2) Develop a practical approach in managing patients on biologics with respect to the following clinical scenarios: vaccinations, pregnancy, infections, hepatitis and surgery considerations

**Panel Q&A** (15 mins) - facilitated by Dr. Bourcier

**Getting to the Root of the Problem: *Delving into psoriasis, common comorbidities, and therapeutic options.***

**Saturday April 12<sup>th</sup>, 2008**

**10:45am to 12:00pm**

**Objectives:**

The accredited activity will be led by the national and international experts in dermatology and will shed light on the latest data with biological treatment to improve patient outcomes in moderate-to-severe plaque psoriasis. Following the symposium, participants should be able to: 1) describe and discuss the practical management of patients with moderate-to-severe plaque psoriasis; 2) discuss appropriate patient selection and patient counseling once a biologic is considered; and 3) identify and discuss the condition's common comorbidities and rationale for biologic therapy. The symposium is supported by an unrestricted educational grant by Schering-Plough Canada.

**Faculty**

**1. Dr. Ronald B. Vender (Chair)**

Associate Professor, McMaster University  
Head of Dermatology, Department of Medicine  
Dermatology Consultant, St. Joseph's Healthcare  
Hamilton Civic Hospital  
Hamilton, Ontario

**2. Professor Giampiero Girolomoni**

Professor of Dermatology  
Head of the Department of Dermatology  
University of Verona School of Medicine  
Verona, Italy

**3. Dr. Chih-Ho Hong**

Clinical Assistant Professor, University of British Columbia  
Diplomate, American Board of Dermatology  
St. Paul's Hospital  
Vancouver, BC

**Agenda:**

Practical considerations: *Risk versus benefit of biologics*

Dr. Ronald Vender

Bringing clarity to psoriasis: *Understanding the condition, its comorbidities, and rationale for biologic treatment*

Prof. Giampiero  
Girolomoni

Starting from scratch: *Case studies of my first 10 psoriasis patients on biologic therapy*

Dr. Chih-Ho Hong

**New Treatment Modalities for Non-Melanoma Skin Cancer**

**Saturday April 12<sup>th</sup>, 2008**

**4:15pm to 6:00pm**

**Program Objectives:**

After attending the session, participants should be able to:

- Better understand the new approaches in the treatment of non-melanoma skin cancer
- Incorporate new approaches in the treatment of NMSC into their practice

**Chair**

**Jason K. Rivers, MD, FRCPC**

University of British Columbia, Pacific DermAesthetics,  
Vancouver, BC

**Faculty**

**Ted Rosen, MD**

Baylor College of Medicine,  
Houston, Texas

**Claas Ulrich, MD**

Skin Cancer Center Charité, Department of Dermatology, Venereology and Allergology,  
Charité – University Medical Center Berlin, Germany

**Agenda:**

4:15 Introduction & Welcome

**Jason K. Rivers, MD, FRCPC**

4:45 Squamous Cell in-situ (Bowen's Disease)

**Ted Rosen, MD**

5:15 New Comparative Data in Actinic Keratosis

**Claas Ulrich, MD**

5:45 Q&A and Conclusion

**Jason K. Rivers, MD, FRCPC**